

Bradley A Stohr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189318/publications.pdf>

Version: 2024-02-01

38
papers

1,671
citations

430874

18
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

3025
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease. <i>American Journal of Surgical Pathology</i> , 2022, 46, 392-403. | 3.7 | 9 |
| 2 | Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. <i>Investigative and Clinical Urology</i> , 2022, 63, 27. | 2.0 | 8 |
| 3 | Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. <i>Human Pathology</i> , 2022, 119, 85-93. | 2.0 | 4 |
| 4 | Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. <i>Nature Communications</i> , 2022, 13, 141. | 12.8 | 76 |
| 5 | TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718. | 5.4 | 32 |
| 6 | Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 531-531. | 1.6 | 4 |
| 7 | LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. <i>Pathology Research and Practice</i> , 2022, 232, 153831. | 2.3 | 0 |
| 8 | Invasive poorly differentiated adenocarcinoma of the bladder following augmentation cystoplasty: a multi-institutional clinicopathological study. <i>Pathology</i> , 2021, 53, 214-219. | 0.6 | 4 |
| 9 | Metabolic imaging with hyperpolarized ¹³ C pyruvate magnetic resonance imaging in patients with renal tumors—Initial experience. <i>Cancer</i> , 2021, 127, 2693-2704. | 4.1 | 27 |
| 10 | Pathophysiology, Clinical Manifestations, and Treatment of Lichen Sclerosus: A Systematic Review. <i>Urology</i> , 2020, 135, 11-19. | 1.0 | 64 |
| 11 | Renal Cell Carcinoma With Leiomyomatous Stroma Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. <i>American Journal of Surgical Pathology</i> , 2020, 44, 571-581. | 3.7 | 67 |
| 12 | Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. <i>Cell Stem Cell</i> , 2020, 26, 27-33.e4. | 11.1 | 155 |
| 13 | Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma. <i>Practical Laboratory Medicine</i> , 2020, 21, e00164. | 1.3 | 9 |
| 14 | Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. <i>Prostate</i> , 2020, 80, 1421-1428. | 2.3 | 1 |
| 15 | Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution. <i>Histopathology</i> , 2020, 76, 1084-1090. | 2.9 | 11 |
| 16 | Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer. <i>Modern Pathology</i> , 2020, 33, 1802-1810. | 5.5 | 7 |
| 17 | Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. <i>Prostate</i> , 2020, 80, 653-659. | 2.3 | 17 |
| 18 | Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17025-e17025. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | In Situ Visualization of Telomere Length, Telomere Elongation, and TERT Expression in Single Cells. <i>Current Protocols in Cell Biology</i> , 2019, 85, e97. | 2.3 | 0 |
| 20 | Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 435-445. | 3.7 | 106 |
| 21 | Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 90-95. | 0.4 | 16 |
| 22 | Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.. <i>Journal of Clinical Oncology</i> , 2019, 37, 88-88. | 1.6 | 0 |
| 23 | Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. <i>American Journal of Surgical Pathology</i> , 2018, 42, 927-935. | 3.7 | 167 |
| 24 | Preliminary development of an assay for detection of TERT expression, telomere length, and telomere elongation in single cells. <i>PLoS ONE</i> , 2018, 13, e0206525. | 2.5 | 9 |
| 25 | Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. <i>European Urology</i> , 2018, 74, 668-675. | 1.9 | 34 |
| 26 | Renal cell carcinoma with TFE3 translocation and succinate dehydrogenase B mutation. <i>Modern Pathology</i> , 2017, 30, 407-415. | 5.5 | 28 |
| 27 | Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. <i>European Urology</i> , 2017, 71, 750-759. | 1.9 | 40 |
| 28 | Reply to Chou et al "Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution" <i>Mod Pathol</i> 2017; in press.. <i>Modern Pathology</i> , 2017, 30, 1509-1511. | 5.5 | 4 |
| 29 | Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11575-11575. | 1.6 | 0 |
| 30 | Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. <i>Modern Pathology</i> , 2016, 29, 1012-1027. | 5.5 | 54 |
| 31 | Nuclear size is sensitive to NTF2 protein levels dependent on Ran binding. <i>Journal of Cell Science</i> , 2016, 129, 1115-27. | 2.0 | 39 |
| 32 | Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction. <i>Autophagy</i> , 2015, 11, 527-537. | 9.1 | 17 |
| 33 | The Shelterin TIN2 Subunit Mediates Recruitment of Telomerase to Telomeres. <i>PLoS Genetics</i> , 2015, 11, e1005410. | 3.5 | 47 |
| 34 | Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. <i>Nature</i> , 2014, 512, 198-202. | 27.8 | 519 |
| 35 | FPA144, a humanized monoclonal antibody for both <i>FGFR2</i>-amplified and nonamplified, <i>FGFR2b</i>-overexpressing gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15074-e15074. | 1.6 | 9 |
| 36 | In situ visualization of telomere elongation patterns in human cells. <i>Nucleic Acids Research</i> , 2013, 41, e176-e176. | 14.5 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The Terminal Telomeric DNA Sequence Determines the Mechanism of Dysfunctional Telomere Fusion. <i>Molecular Cell</i> , 2010, 39, 307-314. | 9.7 | 27 |
| 38 | ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells. <i>Cancer Research</i> , 2008, 68, 5309-5317. | 0.9 | 32 |